Analysts have been eager to weigh in on the Healthcare sector with new ratings on Cooper Co (NYSE: COO), Invuity (NASDAQ: IVTY) and EDAP TMS (NASDAQ: EDAP).
Cooper Co (NYSE: COO)
In a report released today, Steven Lichtman from Oppenheimer maintained a Hold rating on Cooper Co (NYSE: COO), with a price target of $265. The company’s shares opened today at $237.05.
Lichtman commented:
“Cooper’s F2Q18 sales of $631M exceeded our/Street’s $624M/$626M estimates led by continued strength in toric lenses and daily Silicon Hydrogel. Overall, CVI grew 6% pro forma, with Americas higher sequentially as a result of management efforts to minimize customer use of the gray market (EMEA was slower sequentially as a result of this). $2.86 came in roughly in line with our estimate of $2.85 as the higher sales were offset by slightly lower operating margin versus our estimate. Management sees the contact lens market growing in the upper half of its long-term 4-6% growth estimate. Management slightly raised its FY18 pro forma sales guidance. EPS guidance was maintained despite unfavorable incremental FX moves, reflecting underlying operational performance and PARAGARD accretion.”
According to TipRanks.com, Lichtman has currently no stars on a ranking scale of 0-5 stars, with an average return of -4.0% and a 54.0% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Integra Lifesciences, Wright Medical Group, and K2M Group Holdings.
Cooper Co has an analyst consensus of Moderate Buy, with a price target consensus of $266.50.
See today’s analyst top recommended stocks >>
Invuity (NASDAQ: IVTY)
In a report released today, Suraj Kalia from Northland Securities maintained a Buy rating on Invuity (NASDAQ: IVTY), with a price target of $6. The company’s shares opened today at $3.65.
Kalia noted:
“We recently had a chat with the new CEO to better grasp the state of affairs & the transition period needed to measure the ROI on the new strategy. Admittedly, a lot can go wrong. The proof will be in the pudding, although we contend that the new CEO deserves some grace period to right the ship.”
According to TipRanks.com, Kalia is a 4-star analyst with an average return of 8.6% and a 58.6% success rate. Kalia covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Apollo Endosurgery Inc.
Invuity has an analyst consensus of Moderate Buy, with a price target consensus of $5.50.
EDAP TMS (NASDAQ: EDAP)
H.C. Wainwright analyst Swayampakula Ramakanth maintained a Buy rating on EDAP TMS (NASDAQ: EDAP) today and set a price target of $6.50. The company’s shares opened today at $4, close to its 52-week high of $4.25.
Ramakanth wrote:
“Bolster HIFU Sales; Reiterate Buy FDA Approved Focal One. On June 7, EDAP announced that the US FDA has approved the company’s Focal One device for the ablation of prostate tissue. Recall, Focal One is a second generation High-Intensity Focused Ultrasound (HIFU) device designed to treat localized prostate cancer. Compared to the company’s first generation Ablatherm device, Focal One allows urologists to visualize and excise the diseased tissue with much greater precision, which could result in the ablation of an even smaller portion of the prostate and potentially lowering side effects such as incontinence and erectile dysfunction.”
According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 8.4% and a 40.9% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Diffusion Pharmaceuticals Inc, IntelGenx Technologies, and Trillium Therapeutics.
EDAP TMS has an analyst consensus of Moderate Buy, with a price target consensus of $6.50.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
